Results 11 to 20 of about 28,326 (256)
ctDNA as a biomarker of progression in oesophageal adenocarcinoma [PDF]
ESMO Open, 2021 Abstract Background: The incidence of oesophageal adenocarcinoma (OAC) is rapidly increasing and despite improvements in treatment, the five-year survival rate remains poor. Prognostic biomarkers that address the genomic heterogeneity in this highly complex disease will aid the development of precision therapeutics and improve patient survival.
Vanessa F. Bonazzi +10 more
openaire +4 more sources
Liquid biopsy in CNS tumors: Current status & future perspectives
Indian Journal of Pathology and Microbiology, 2022 Precise classification of central nervous system (CNS) malignancies is vital for the treatment and prognostication. Identification of noninvasive markers can be of importance to guide treatment decisions and in monitoring treatment response.
Nuzhat Husain +3 more
doaj +1 more source
Fragmentomic cfDNA Patterns in Noninvasive Prenatal Testing and Beyond
Journal of Biomedicine and Translational Research, 2021 The release of fetoplacental cell-free DNA (cfDNA) into the maternal bloodstream opened up new avenues towards noninvasive prenatal testing (NIPT) for aneuploidies, hereditary DNA mutations and other pregnancy-related developmental disorders ...
Kavish Kohabir +2 more
doaj +1 more source
Identification of Genetic Alterations by Circulating Tumor DNA in Leiomyosarcoma: A Molecular Analysis of 73 Patients [PDF]
Journal of Immunotherapy and Precision Oncology, 2020 Background: Leiomyosarcoma is a malignant mesenchymal tumor of cells of smooth muscle lineage arising commonly in retroperitoneum, uterus, large veins, and the limbs.
Junaid Arshad +5 more
doaj +1 more source
Société Internationale d’Urologie Journal, 2023 None.
Manishkumar S. Patel, Liang Wang
doaj +1 more source
ctDNA as a novel and promising approach for cancer diagnosis
EXCLI Journal : Experimental and Clinical Sciences, 2023 Hepatocellular carcinoma (HCC) is one of the most prevalent forms of cancer worldwide. Therefore, it is essential to diagnose and treat HCC patients promptly.
Negin Biglari +4 more
doaj +1 more source
ctDNA as a prognostic biomarker in resectable CLM: Systematic review and meta-analysis
Open Life Sciences, 2023 Cell-free circulating tumor DNA (ctDNA) is synthesized by tumor cells, including metastatic tumors, and circulates in the bloodstream. Evidence suggests that ctDNA is a potential predictive and prognostic biomarker for colorectal cancer (CRC), but its ...
Wang Da +10 more
doaj +1 more source
Description of the calf thymus DNA-malathion complex behavior by multi-spectroscopic and molecular modeling techniques: EMF at low and high frequency approaches [PDF]
Iranian Journal of Basic Medical Sciences, 2021 Objective(s): Small molecules can bind to DNA via covalent or non-covalent interactions, which results in altering or inhibiting the function of DNA. Thus, understanding the interaction patterns of medicines or other small molecules can be very crucial ...
Tahmineh Sohrabi +5 more
doaj +1 more source
, 2023 Patients with detectable ctDNA after radical-intent treatment of metastatic spread from colorectal cancer (mCRC) have a very high risk of recurrence, which may be prevented with intensified adjuvant chemotherapy (aCTh).
Torben Frøstrup Hansen (12987262) +10 more
core +1 more source
Chinese Journal of Lung Cancer, 2021 Lung cancer is the most common malignant tumor in the world, among which non-small cell lung cancer (NSCLC) accounts for about 85% of the total number of lung cancers.
Shihua DOU, Hongsheng XIE, Lin YANG
doaj +1 more source